MLL/KMT2A antibody (AA 3751-3968)

Catalog No. ABIN969286

This Mouse Monoclonal antibody specifically detects MLL/KMT2A in IHC and ELISA. It exhibits reactivity toward Human and has been mentioned in 3+ publications.

Quick Overview for MLL/KMT2A antibody (AA 3751-3968) (ABIN969286)

Target: MLL/KMT2A (MLL) (Myeloid/lymphoid Or Mixed-Lineage Leukemia (MLL))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This MLL/KMT2A antibody is un-conjugated

Application: Immunohistochemistry (IHC), ELISA

Clone: 10F8D7

Product Details anti-MLL/KMT2A Antibody

Binding Specificity: AA 3751-3968

Purpose: MLL Antibody

Purification: Ascitic fluid

Immunogen: Purified recombinant fragment of MLL (aa3751-3968) expressed in E. Coli.

Isotype: IgG1

Application Details

Application Notes: ELISA: 1/10000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

References for anti-MLL/KMT2A antibody (ABIN969286)

Nigro, Sainati, Leszl, Mirabile, Spinelli, Consarino, Di Cataldo, Magro, Felix, Basso: "Acute differentiated dendritic cell leukemia: a variant form of pediatric acute myeloid leukemia with MLL translocation." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 21, Issue 2, pp. 360-2, (2007) (PubMed).

Partida-Pérez, Domínguez, Sánchez-Corona, Castañeda-Cisneros, García-González, López-Cardona, Rivera: "Constitutional duplication 11q23 de novo involving the MLL gene." in: Genetic counseling (Geneva, Switzerland), Vol. 17, Issue 2, pp. 155-9, (2006) (PubMed).

Kadkol, Bruno, Oh, Schmidt, Lindgren: "MLL-SEPT6 fusion transcript with a novel sequence in an infant with acute myeloid leukemia." in: Cancer genetics and cytogenetics, Vol. 168, Issue 2, pp. 162-7, (2006) (PubMed).

Target Details for MLL/KMT2A

Target: MLL/KMT2A (MLL) (Myeloid/lymphoid Or Mixed-Lineage Leukemia (MLL))

Alternative Name: MLL

Background: Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila). Eukaryotic RNA polymerase II mediates the synthesis of mature and functional messenger RNA. This is a multistep process, called the transcription cycle,that includes five stages: preinitiation, promoter, clearance, elongation and termination. Elongation is thought to be a critical stage for the regulation of gene expression. ELL (11-19 lysine-rich leukemia protein, also designated MEN) functions as an RNA polymerase II elongation factor that increases the rateof transcription by suppressing transient pausing by RNA polymerase II. Also, ELL is thought to regulate cellular proliferation. ELL is abundantly expressed in peripheral blood leukocytes, skeletal muscle, placenta and testis, and has lower expression in spleen, thymus, heart, brain, lung, kidney, liver and ovary.The gene encoding human ELL, which maps to chromosome 19p13.1, is one of several genes which undergo translocation with the MLL gene on chromo-some 11q23 in acute myeloid leukemia. MLL (myeloid/lymphoid leukemia,also designated ALL-1 and HRX) is a 430 kDa protein that regulates embryonal and hematopoietic development.

Gene ID: 4297

UniProt: Q03164

Pathways: Warburg Effect